1.Robot-assisted laparoscopic enucleation in the treatment of leiomyosarcoma of urinary bladder: A case report.
Zhongyi ZENG ; Xiao WU ; Kai PENG ; Da REN ; Xuan ZHU ; Lei ZHANG
Journal of Central South University(Medical Sciences) 2023;48(5):782-788
Leiomyosarcoma of urinary bladder (LMS-UB) is a highly malignant mesenchymal tumor, accounting for less than 0.5% of all bladder malignancies, with a predominant clinical presentation of hematuria. Here we report a case of low-grade LMS-UB. A 44-year-old male patient was admitted to the hospital with urodynia for 2 weeks. The patient's pelvis CT showed a mass on the right part of the bladder. For this reason, he was initially diagnosed with bladder cancer. We performed a robot-assisted laparoscopic enucleation of the bladder tumor and low-grade LMS-UB was diagnosed with the histopathological examination. He underwent 5 cycles of adjuvant chemotherapy after surgery. At 19months postoperative follow-up, the patient had no symptoms, recurrence, or distant metastasis. There is no report on the treatment of LMS-UB with minimally invasive enucleation worldwide. This case provides a new comprehensive treatment method of enucleation combined with adjuvant chemotherapy for early low-grade LMS-UB to reduce complications and improve patients' quality of life after surgery.
Male
;
Humans
;
Adult
;
Urinary Bladder/surgery*
;
Leiomyosarcoma/secondary*
;
Robotics
;
Quality of Life
;
Pelvis/pathology*
;
Urinary Bladder Neoplasms/pathology*
;
Laparoscopy/methods*
2.Expert consensus of multi-disciplinary collaboration on bladder-preserving treatment for bladder cancer in China.
Chinese Journal of Oncology 2022;44(3):209-218
Objective: Bladder cancer is one of the most common malignant tumors in urology. Urothelial carcinoma accounts for about 90% of all bladder malignancies. According to whether the tumor invades the bladder muscle, it can be divided into non-muscle invasive bladder cancer and muscle invasive bladder cancer. Radical cystectomy is the standard treatment for muscle invasive bladder cancer patients and high-risk non-muscle invasive bladder cancer patients who have failed Bacillus Calmette-Guerin treatment. Due to the comorbidity of bladder cancer and the potential deterioration of the quality of life after surgery, many patients were not suitable or refused for radical cystectomy. Therefore, it is vital to find a bladder-preserving treatment that can achieve cure other than radical cystectomy. Bladder-preserving therapy that balances tumor control and quality of life serves as an alternative and supplement to radical cystectomy. This consensus is based on contemporary evidence-based medicine, combined with the native clinical practice of bladder preservation in a multidisciplinary treatment manner. To some extent, this consensus serves as a guidance for bladder-preservation therapy of bladder cancer in China. Several issues are extensively discussed here, including organizational structure and workflow of multidisciplinary treatment, the selection of patients for bladder-preserving therapy, treatment options and regimens, follow-up, as well as regimen choices of recurrence after bladder-preserving therapy.
Carcinoma, Transitional Cell/surgery*
;
Combined Modality Therapy
;
Consensus
;
Humans
;
Neoplasm Invasiveness/pathology*
;
Quality of Life
;
Urinary Bladder/surgery*
;
Urinary Bladder Neoplasms/surgery*
3.Correlation between adipokine and clinicopathological features and prognosis in upper tract urothelial carcinoma.
Xiang DAI ; Fei WANG ; Yi Qing DU ; Yu Xuan SONG ; Tao XU
Journal of Peking University(Health Sciences) 2022;54(4):605-614
OBJECTIVE:
To investigate the correlation between expression levels of adipokine and clinicopathological features and prognosis of patients with upper tract urothelial carcinoma (UTUC) based on immunohistochemical staining and bioinformatics analysis.
METHODS:
The 8 adipokines in this study included adiponectin (AdipoQ), leptin (LEP), interleukin (IL)-6, IL-10 and their receptors (AdipoR1, AdipoR2, LEPR, IL-6R, IL-10RA, IL-10RB). Tissue samples of patients with UTUC who underwent surgical treatment in Peking University People's Hospital from January 2014 to April 2021 were selected for immunohistochemical staining. Their quantitative gene expression data were calculated by H-Score, and relevant clinical and follow-up data were collected retrospectively. Transcription group sequencing data of UTUC patients in Gene Expression Omnibus database (GSE134292 dataset) were downloaded for comparison. Chi-square test or t-test was used to compare the expression level of adipokine between non-muscle invasive group and muscle invasive group. Univariate and multivariate Cox regression analysis and Kaplan-Meier survival curve were utilized to analyze independent predictors of overall survival (OS), disease-free survival (DFS), intravesical recurrence-free survival (IVRFS) in the both cohorts. The P < 0.05 was considered statistically significant.
RESULTS:
In the study, 63 tissue samples of the patients with UTUC who underwent surgical treatment in Peking University People's Hospital and 57 UTUC patients in GSE134292 dataset were selected. In immunohistochemical cohort, the expressions of AdipoQ (P=0.003 6), AdipoR1 (P=0.006 5), LEP (P=0.007 7), IL-10 (P=0.006 9), and IL-10RA (P=0.008 9) were statistically higher in muscle invasive group. In GSE134292 cohort, the expressions of AdipoR1 (P=0.000 4), AdipoR2 (P=0.000 4), IL-6 (P=0.005 0), IL-10 (P=0.001 7), and IL-10RA (P=0.008 1) were statistically higher in muscle invasive group. Kaplan-Meier survival curve and multivariate Cox regression analysis showed that high IL-10RA expression was an independent predictive factor of IVRFS (P=0.044, HR=0.996, 95%CI: 0.992-0.998) in immunohistochemical cohort, which was confirmed in GSE134292 cohort (P=0.014, HR=0.515, 95%CI: 0.304-0.873).
CONCLUSION
The expression levels of AdipoQ, AdipoR1, IL-10, and IL-10RA were correlated with tumor stage, suggesting that these adipokines played important roles in tumor progression. IL-10RA was an independent predictor of IVRFS, suggesting that IL-10 and its receptor played a critical role in tumor recurrence.
Adipokines
;
Carcinoma, Transitional Cell/surgery*
;
Humans
;
Interleukin-10
;
Neoplasm Recurrence, Local
;
Prognosis
;
Retrospective Studies
;
Urinary Bladder Neoplasms/surgery*
;
Urologic Neoplasms/pathology*
4.Computed tomography and magnetic resonance imaging evaluation of pelvic lymph node metastasis in bladder cancer.
Yong LI ; Feiyu DIAO ; Siya SHI ; Kaiwen LI ; Wangshu ZHU ; Shaoxu WU ; Tianxin LIN
Chinese Journal of Cancer 2018;37(1):3-3
BACKGROUND:
Accurate evaluation of lymph node metastasis in bladder cancer (BCa) is important for disease staging, treatment selection, and prognosis prediction. In this study, we aimed to evaluate the diagnostic accuracy of computed tomography (CT) and magnetic resonance imaging (MRI) for metastatic lymph nodes in BCa and establish criteria of imaging diagnosis.
METHODS:
We retrospectively assessed the imaging characteristics of 191 BCa patients who underwent radical cystectomy. The data regarding size, shape, density, and diffusion of the lymph nodes on CT and/or MRI were obtained and analyzed using Kruskal-Wallis test and χ test. The optimal cutoff value for the size of metastatic node was determined using the receiver operating characteristic (ROC) curve analysis.
RESULTS:
A total of 184 out of 3317 resected lymph nodes were diagnosed as metastatic lymph nodes. Among 82 imaging-detectable lymph nodes, 51 were confirmed to be positive for metastasis. The detection rate of metastatic nodes increased along with more advanced tumor stage (P < 0.001). Once the ratio of short- to long-axis diameter ≤ 0.4 or fatty hilum was observed in lymph nodes on imaging, it indicated non-metastases. Besides, lymph nodes with spiculate or obscure margin or necrosis indicated metastases. Furthermore, the short diameter of 6.8 mm was the optimal threshold to diagnose metastatic lymph node, with the area under ROC curve of 0.815.
CONCLUSIONS
The probability of metastatic nodes significantly increased with more advanced T stages. Once lymph nodes are detected on imaging, the characteristic signs should be paid attention to. The short diameter > 6.8 mm may indicate metastatic lymph nodes in BCa.
Adult
;
Aged
;
Aged, 80 and over
;
Female
;
Humans
;
Lymph Node Excision
;
Lymph Nodes
;
pathology
;
Lymphatic Metastasis
;
diagnostic imaging
;
pathology
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Pelvic Neoplasms
;
diagnostic imaging
;
pathology
;
secondary
;
surgery
;
Pelvis
;
diagnostic imaging
;
pathology
;
Tomography, X-Ray Computed
;
Urinary Bladder Neoplasms
;
diagnostic imaging
;
pathology
;
surgery
5.Hand-Assisted Laparoscopic Surgery: A Versatile Tool for Colorectal Surgeons.
Ju Yong CHEONG ; Christopher J YOUNG
Annals of Coloproctology 2017;33(4):125-129
PURPOSE: Hand-assisted laparoscopic surgery (HALS) is a minimally invasive surgical technique with the combined benefits of laparoscopic surgery while allowing the use of the surgeon's hand for better tactile control. Obesity has been associated with higher conversion rates with multiport laparoscopic surgery, but not with HALS. This study aimed to examine the versatility of HALS in various clinical contexts. METHODS: All HALSs performed at 2 major tertiary centers in Sydney were prospectively collected for retrospective analysis. Variables including age, sex, body mass index (BMI), previous surgeries, pathologies including size and T-stage, and the number of conversions to a midline laparotomy were examined. RESULTS: A total of 121 HALS colorectal resections were analyzed. The median age of the patients was 62 years, with 63.6% being women. Seven patients required conversion to a midline laparotomy. Of the 121 patients, 50.2% were overweight or obese, and 52.9% had undergone previous abdominal/pelvic operations. However, neither obesity nor abdominal adhesions from previous operations were an indication for conversion to an open laparotomy in any of the 7 converted patients. The presence of intra-abdominal adhesions did not impact the operative time. HALS allowed access to the entire colon and rectum and allowed resection of the bladder, uterus, and ureter, when these organs were involved. CONCLUSION: HALS is a versatile, minimally invasive technique, which is independent of the patient's BMI, for performing a colorectal resection.
Body Mass Index
;
Colon
;
Colorectal Surgery
;
Female
;
Hand
;
Hand-Assisted Laparoscopy*
;
Humans
;
Laparoscopy
;
Laparotomy
;
Obesity
;
Operative Time
;
Overweight
;
Pathology
;
Prospective Studies
;
Rectum
;
Retrospective Studies
;
Surgeons*
;
Ureter
;
Urinary Bladder
;
Uterus
6.Fibroblast Growth Factor Receptor 1 Overexpression Is Associated with Poor Survival in Patients with Resected Muscle Invasive Urothelial Carcinoma.
Seungtaek LIM ; Myoung Ju KOH ; Hyeon Joo JEONG ; Nam Hoon CHO ; Young Deuk CHOI ; Do Yeun CHO ; Hoi Young LEE ; Sun Young RHA
Yonsei Medical Journal 2016;57(4):831-839
PURPOSE: To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients. MATERIALS AND METHODS: We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3). RESULTS: There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95% confidence interval: 1.27-3.90, p=0.006) in multivariate analysis. CONCLUSION: Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.
Adult
;
Aged
;
Aged, 80 and over
;
Carcinoma/*metabolism/*mortality/surgery
;
Cystectomy
;
Female
;
Humans
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Muscles/pathology
;
Neoplasm Invasiveness
;
Prognosis
;
Proportional Hazards Models
;
Receptor, ErbB-2/metabolism
;
Receptor, Fibroblast Growth Factor, Type 1/*metabolism
;
Receptor, Fibroblast Growth Factor, Type 3/metabolism
;
Retrospective Studies
;
Survival Rate
;
Urinary Bladder Neoplasms/*metabolism/*mortality/surgery
;
Urothelium/pathology
7.Efficacy and oncologic safety of nerve-sparing radical hysterectomy for cervical cancer: a randomized controlled trial.
Ju Won ROH ; Dong Ock LEE ; Dong Hoon SUH ; Myong Cheol LIM ; Sang Soo SEO ; Jinsoo CHUNG ; Sun LEE ; Sang Yoon PARK
Journal of Gynecologic Oncology 2015;26(2):90-99
OBJECTIVE: A prospective, randomized controlled trial was conducted to evaluate the efficacy of nerve-sparing radical hysterectomy (NSRH) in preserving bladder function and its oncologic safety in the treatment of cervical cancer. METHODS: From March 2003 to November 2005, 92 patients with cervical cancer stage IA2 to IIA were randomly assigned for surgical treatment with conventional radical hysterectomy (CRH) or NSRH, and 86 patients finally included in the analysis. Adequacy of nerve sparing, radicality, bladder function, and oncologic safety were assessed by quantifying the nerve fibers in the paracervix, measuring the extent of paracervix and harvested lymph nodes (LNs), urodynamic study (UDS) with International Prostate Symptom Score (IPSS), and 10-year disease-free survival (DFS), respectively. RESULTS: There were no differences in clinicopathologic characteristics between two groups. The median number of nerve fiber was 12 (range, 6 to 21) and 30 (range, 17 to 45) in the NSRH and CRH, respectively (p<0.001). The extent of resected paracervix and number of LNs were not different between the two groups. Volume of residual urine and bladder compliance were significantly deteriorated at 12 months after CRH. On the contrary, all parameters of UDS were recovered no later than 3 months after NSRH. Evaluation of the IPSS showed that the frequency of long-term urinary symptom was higher in CRH than in the NSRH group. The median duration before the postvoid residual urine volume became less than 50 mL was 11 days (range, 7 to 26 days) in NSRH group and was 18 days (range, 10 to 85 days) in CRH group (p<0.001). No significant difference was observed in the 10-year DFS between two groups. CONCLUSION: NSRH appears to be effective in preserving bladder function without sacrificing oncologic safety.
Adenocarcinoma/mortality/pathology/surgery
;
Adult
;
Carcinoma, Adenosquamous/mortality/pathology/surgery
;
Carcinoma, Squamous Cell/mortality/pathology/surgery
;
Female
;
Humans
;
Hysterectomy/adverse effects/*methods
;
Middle Aged
;
*Organ Sparing Treatments/adverse effects/methods
;
Pelvis/*innervation/surgery
;
Recovery of Function
;
Survival Analysis
;
Treatment Outcome
;
Urinary Bladder/*innervation/physiology/surgery
;
Uterine Cervical Neoplasms/mortality/pathology/*surgery
;
Uterus/*innervation/surgery
8.The prognostic impact of perioperative blood transfusion on survival in patients with bladder urothelial carcinoma treated with radical cystectomy.
Joong Sub LEE ; Hyung Suk KIM ; Chang Wook JEONG ; Cheol KWAK ; Hyeon Hoe KIM ; Ja Hyeon KU
Korean Journal of Urology 2015;56(4):295-304
PURPOSE: The aim of our study was to assess the influence of perioperative blood transfusion (PBT) on survival outcomes following radical cystectomy (RC) and pelvic lymph node dissection (PLND). MATERIALS AND METHODS: We reviewed and analyzed the clinical data of 432 patients who underwent RC for bladder cancer from 1991 to 2012. PBT was defined as the transfusion of allogeneic red blood cells during RC or postoperative hospitalization. RESULTS: Of all patients, 315 patients (72.9%) received PBT. On multivariate logistic regression analysis, female gender (p=0.015), a lower preoperative hemoglobin level (p=0.003), estimated blood loss>800 mL (p<0.001), and performance of neoadjuvant chemotherapy (p<0.001) were independent risk factors related to requiring perioperative transfusions. The receipt of PBT was associated with increased overall mortality (hazard ratio, 1.91; 95% confidence interval, 1.25-2.94; p=0.003) on univariate analysis, but its association was not confirmed by multivariate analysis (p=0.058). In transfused patients, a transfusion of >4 packed red blood cell units was an independent predictor of overall survival (p=0.007), but not in cancer specific survival. CONCLUSIONS: Our study was not conclusive to detect a clear association between PBT and survival after RC. However, the efforts should be made to continue limiting the overuse of transfusion especially in patients who are expected to have a high probability of PBT, such as females and those with a low preoperative hemoglobin level and history of neoadjuvant chemotherapy.
Aged
;
*Blood Transfusion/methods/mortality
;
*Carcinoma, Transitional Cell/mortality/pathology/surgery
;
Disease-Free Survival
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Lymph Node Excision/*methods
;
Male
;
Middle Aged
;
Pelvis/pathology/surgery
;
Perioperative Care/methods
;
Prognosis
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Treatment Outcome
;
Urinary Bladder/pathology
;
*Urinary Bladder Neoplasms/mortality/pathology/surgery
9.The Characteristics of Recurrent Upper Tract Urothelial Carcinoma after Radical Nephroureterectomy without Bladder Cuff Excision.
Minyong KANG ; Chang Wook JEONG ; Cheol KWAK ; Hyeon Hoe KIM ; Ja Hyeon KU
Yonsei Medical Journal 2015;56(2):375-381
PURPOSE: To investigate oncological outcomes based on bladder cuff excision (BCE) during radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC) and to provide clinical evidence of tumor recurrence in patients without BCE. MATERIALS AND METHODS: We retrospectively collected data of 372 consecutive patients who underwent RNU at our institution from May 1989 through October 2010. After excluding some data, we reviewed 336 patients for the analysis. RESULTS: Of the patients who underwent RNU with BCE (n=279, 83.0%) and without BCE (n=57, 17.0%), patients without BCE had poorer cancer-specific and overall survival rates. Among 57 patients without BCE, 35 (61.4%) experienced tumor recurrence. Recurrence at the remnant ureter resulted in poor oncological outcomes compared to those in patients with bladder recurrence, but better outcomes were observed compared to recurrence at other sites. No significant predictors for tumor recurrence at the remnant ureter were identified. In patients without BCE, pathological T stage [hazard ratio (HR), 5.73] and lymphovascular invasion (HR, 3.65) were independent predictors of cancer-specific survival, whereas age (HR, 1.04), pathological T stage (HR, 5.11), and positive tumor margin (HR, 6.50) were independent predictors of overall survival. CONCLUSION: Patients without BCE had poorer overall and cancer-specific survival after RNU than those with BCE. Most of these patients experienced tumor recurrence at the remnant ureter and other sites. Patients with non-organ confined UTUC after RNU without BCE may be considered for adjuvant chemotherapy with careful follow-up.
Adult
;
Aged
;
Carcinoma, Transitional Cell/*surgery
;
Chemotherapy, Adjuvant
;
Female
;
Humans
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/*pathology
;
Nephrectomy/*methods
;
Retrospective Studies
;
Survival Rate
;
Treatment Outcome
;
Ureter/*surgery
;
Ureteral Neoplasms/*surgery
;
Urinary Bladder/pathology
;
Urinary Bladder Neoplasms/*pathology
;
Urologic Neoplasms/pathology/*surgery
;
*Urologic Surgical Procedures
;
Urothelium/*pathology
10.Is Intravesical Bacillus Calmette-Guerin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate.
Kyung Sik HAN ; Dalsan YOU ; In Gab JEONG ; Teakmin KWON ; Bumsik HONG ; Jun Hyuk HONG ; Hanjong AHN ; Tai Young AHN ; Choung Soo KIM
Journal of Korean Medical Science 2015;30(3):252-258
The objective of this study was to evaluate the risk of recurrence in patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) after intravesical instillation with chemotherapeutic agents or Bacillus Calmette-Guerin (BCG) therapy. A cohort of 746 patients with intermediate-risk NMIBC comprised the study group. The primary outcome was time to first recurrence. The recurrence rates of the transurethral resection (TUR) alone, chemotherapy, and BCG groups were determined using Kaplan-Meier analysis. Risk factors for recurrence were identified using Cox regression analysis. In total, 507 patients (68.1%), 78 patients (10.5%), and 160 (21.4%) underwent TUR, TUR+BCG, or TUR+chemotherapy, respectively. After a median follow-up period of 51.7 months (interquartile range=33.1-77.8 months), 286 patients (38.5%) developed tumor recurrence. The 5-yr recurrence rates for the TUR, chemotherapy, and BCG groups were 53.6%+/-2.7%, 30.8%+/-5.7%, and 33.6%+/-4.7%, respectively (P<0.001). Chemotherapy and BCG treatment were found to be predictors of reduced recurrence. Cox-regression analysis showed that TUR+BCG did not differ from TUR+chemotherapy in terms of recurrence risk. Adjuvant intravesical instillation is an effective prophylactic that prevents tumor recurrence in intermediate-risk NMIBC patients following TUR. In addition, both chemotherapeutic agents and BCG demonstrate comparable efficacies for preventing recurrence.
Adjuvants, Immunologic/*therapeutic use
;
Administration, Intravesical
;
Antineoplastic Agents/*therapeutic use
;
BCG Vaccine/*therapeutic use
;
Female
;
Follow-Up Studies
;
Humans
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/*pathology
;
Neoplasm Staging
;
Risk
;
Treatment Outcome
;
Urinary Bladder/pathology
;
Urinary Bladder Neoplasms/*drug therapy/pathology/surgery

Result Analysis
Print
Save
E-mail